Navigation Links
Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
Date:2/24/2011

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report fourth quarter and year-end 2010 financial results on Thursday, March 3, 2011, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Thursday, March 3, 2011 at 5:00 p.m. Eastern Standard Time to discuss its fourth quarter and year-end 2010 financial results and highlights.  A live webcast of the call will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 62030425.  The webcast and telephone replay will be available through March 17, 2011.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys has initiated a Phase IIb study of ANA598, the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: ... announced financial results of the three months ended November ... noninvasive treatment of cardiovascular diseases. In addition, the Company, ... , commenced operations on July 1, 2010 under its ...
... (NYSE: CVS ) today announced that it ... jointly lead its CVS/pharmacy business, reporting directly to Larry ... Effective immediately, Mike Bloom, EVP Merchandising and Supply Chain, ... will take over the management of the company,s retail ...
Cached Medicine Technology:Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4CVS Caremark Announces Interim Leadership for Retail Business 2CVS Caremark Announces Interim Leadership for Retail Business 3
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... Obesity and insulin resistance are almost inevitably associated with increases ... can deteriorate to hepatitis and liver failure. A real ... livers make more fat. Insulin resistance occurs when the ... The signals to make lipid after a meal come ...
... in the country to offer skin transplant surgery as ... skin disease vitiligo. The surgery, known as melanocyte-keratinocyte ... normally pigmented areas of the body and transferring them ... It is performed under local anesthesia as an outpatient ...
... 10 million American women of childbearing age suffer from ... infertility due to endometriosis, a puzzling condition where cells ... the endometrium begin to colonize other organs and ... of gynecologic laparoscopic surgeons explores endometriosis from both the ...
... , TUESDAY, Oct. 25 (HealthDay News) -- Researchers have ... major effect on the rate at which men experience ... included 144 experienced U.S. male pilots over the age ... simulator test three times over two years. The participants ...
... A Heart and Stroke Foundation study has found that ... following a heart attack and their health status declines ... The AMI55 study found that women between the ages ... recurrences of chest pain, and worse quality of life than ...
... DALLAS Oct. 25, 2011 A simple blood test ... heart disease, researchers at UT Southwestern Medical Center have found. ... and smoking-related medical expenses and loss of productivity exceeds $167 ... Prevention. Levels of a lung protein found in the blood ...
Cached Medicine News:Health News:Penn study explains paradox of insulin resistance genetics 2Health News:Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo 2Health News:Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 2Health News:Close-up on endometriosis at 40th AAGL Global Congress 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 4Health News:Aging Brain's Decline May Hinge on a Gene 2Health News:Quality-of-life for women an issue: in some matters of the heart, women do not fare as well as men 2Health News:Blood test could identify smokers at higher risk for heart disease, UT Southwestern researchers find 2
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
... cannula allows atraumatic access through ... aspiration of subretinal fluids. ... end of cannula. Luer ... connection to a backflush handle ...
... Ultra thin wall .90 ... maximum flow rate, available in ... for easy insertion through sclerotomy. ... in) silicone tube for infusion ...
PLX Series Sealed CO2 OEM Lasers....
Medicine Products: